Valiant Labs Monitoring Agency Report for Q4FY26 Shows No Deviation in Fund Utilization
Valiant Laboratories Limited's Monitoring Agency Report for Q4FY26 confirms no deviation in the utilization of ₹814.69 crore raised via Rights Issue. Funds were used for promoter loan adjustments, promoter loan repayment, capex, and general corporate purposes. The Audit Committee and Board reviewed the report on May 14, 2026.
The report confirms proper utilization of funds from a rights issue, which is a material event for investors. It addresses concerns about fund usage and compliance, providing transparency and potentially boosting investor confidence.
The report indicates that the company has utilized the funds raised from the rights issue as per the stated objects, with no deviations. This suggests good financial management and adherence to disclosure requirements.
Valiant Laboratories Limited has submitted its Monitoring Agency Report for the quarter ended March 31, 2026. The report, issued by India Ratings and Research Private Limited, confirms that the proceeds raised through the company's Rights Issue, which had a Letter of Offer dated July 15, 2025, have been utilized appropriately for the objects stated in the offer document.
The Rights Issue period was from July 28, 2025, to August 8, 2025, raising ₹814.69 crore (INR 8,146.88 Lakhs) through the issuance of 1,08,62,500 rights equity shares at ₹75 per share.
The utilization of funds was as follows: ₹580.05 crore towards the adjustment of unsecured loans of promoters, ₹13.95 crore for the repayment of outstanding loans of Dhanvallabh Ventures LLP, ₹18.04 crore for capital expenditure, ₹195.65 crore for general corporate purposes, and ₹7.00 crore for issue-related expenses.
All object(s) for fund utilization, including capital expenditure and general corporate purposes, are on-going or completed as per the offer document and no significant delays have been reported. The report also confirms that there has been no deviation from the stated objects of the issue, based on management undertakings and the Statutory Auditor Certificate dated April 22, 2026, issued by Raman S Shah & Co.
The Audit Committee and the Board of Directors reviewed the report in their meetings held on May 14, 2026. The company has also uploaded this intimation on its website.
What to do with a filing like this
Valiant Laboratories Limited filed this with the NSE as a statutory disclosure, categorised under other regulatory filings. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Valiant Laboratories Limited. Read the original for the full detail.